Merck has licensed Coley Pharmaceutical's VaxImmune for $4 million up front and up to $33 million in milestones plus royalties. Merck gains the development rights to use VaxImmune in some vaccine programs for infectious diseases and Alzheimer's. VaxImmune is a proprietary Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic or therapeutic vaccines.
- read the release on the licensing deal